Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to determine the safety of RAD001 and the highest dose
of this drug that can be given to people with HER2-positive metastatic breast cancer safely
in combination with trastuzumab. RAD001 has been used in patients with severe rheumatoid
arthritis, in recipients of solid-organ transplants, healthy volunteers and experiments with
animals, and information from those other research studies suggest that this RAD001 may help
to stop cancer cells from growing abnormally.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Dana-Farber Cancer Institute Novartis Pharmaceuticals